X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The new Phase 2 clinical study, which is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda® (memantine) for a six-month period, which will include two 11-week dosing cycles.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Worldwide Clinical Trials
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 30, 2020
Details:
BryoLogyx has entered into two agreements with Neurotrope for its preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for use in clinical trials and commercialization in AD.
Lead Product(s): Bryostatin-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: BryoLogyx Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 10, 2020
Details:
The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health. The study will evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2020
Details:
Petros' cornerstone product would be Metuchen's Stendra® for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring various men's health products.
Lead Product(s): Avanafil
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Petros Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 18, 2020
Details:
Analysis to adjust for significant baseline imbalance in severe impairment battery scores between treatment groups shows improvement in cognitive function.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
